Description
Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995).
Product information
CAS Number: 845273-93-0
Molecular Weight: 211.64
Formula: C7H14ClNO4
Chemical Name: 2-(chloromethyl)oxirane; carbonic acid; prop-2-en-1-amine
Smiles: C=CCN.OC(O)=O.ClCC1CO1
InChiKey: PADGNZFOVSZIKZ-UHFFFAOYSA-N
InChi: InChI=1S/C3H5ClO.C3H7N.CH2O3/c4-1-3-2-5-3;1-2-3-4;2-1(3)4/h3H,1-2H2;2H,1,3-4H2;(H2,2,3,4)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vivo:
Sevelamer carbonate is an anion-exchange resin with the same polymeric structure as that of sevelamer hydrochloride, but with carbonate replacing chloride as the anion. Sevelamer carbonate lowers serum phosphorus levels and calcium-phosphorus product to a similar extent as sevelamer hydrochloride. Additionally, Sevelamer carbonate is associated with significant effects on decreasing low-density lipoprotein cholesterol levels and may cause less metabolic acidosis than sevelamer hydrochloride in vivo. Sevelamer carbonate (oral adminstration; 1% mixed in diet; 2-3 weeks) significantly reduces serum phosphate level in Npt2b-deficient mice. Npt2b attenuates the hyperphosphatemia in control animals and that sevelamer carbonate treatment has an additional benefit in maintaining serum phosphate in the normal range. Sevelamer carbonate (oral adminstration; 1% mixed in diet; 2-3 weeks) does not alter serum phosphate levels in uremic WT mice (10.04 mg/dl , untreated versus 9.67mg/dl , binder-treated mg/dl) but further decreased serum phosphate levels in uremic Npt2b−/− mice in uremic mouse model.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.